EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sarepta Therapeutics Inc (SRPT) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Sarepta Therapeutics Inc $3.11, price $17.50, upside -82.2%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US8036071004

ST Sarepta Therapeutics Inc logo Thin data Sep 24, 2026

Sarepta Therapeutics Inc

SRPT · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $3.11 · Strongly overvalued (−82.2%)
!Quality 35/100
!Mixed Growth (revenue 5y +32.4 %/yr)
!Thin margins · 3.0% net margin (TTM)
!Moderate debt · negative free cash flow
!Trails peers (5/13)
!Moderate moat 49/100
!Insider activity 35/100
!Evidence only low, so the estimate is less certain
!Weak on past: 20 out of 100
Watch Sarepta Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$163.85 $11.93 Fair Value $3.11 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $11.93 – $163.85 · fair‑value band $2.06 – $3.89 · the $17.50 price screens above the $3.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Sarepta Therapeutics in your weekly email

Every Wednesday you see whether Sarepta Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Show more

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Sarepta Therapeutics Inc (SRPT) currently trades at $17.50, while our model-based Fair Value estimate is $3.11, 82.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $2.06 (bear) to $3.89 (bull), the price of $17.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sarepta Therapeutics Inc reported revenue of $2.2B in FY2025 versus $702M in FY2021, a compound +33.0%/yr. Reported net income was −$713M in FY2025.

Key figures

Market cap $1.8B · P/E ratio 51.5 · P/S ratio 0.83 · EPS (TTM) $0.3400 · Net margin −32.5% · Return on equity 4.9% · Return on assets (EBIT) −10.8% · Operating margin 49.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −82%, SRPT screens richer than that median.

Fair Value models

Bear $2.06 Fair Value $3.11 Bull $3.89
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.2571 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $5.40 $7.24 $10.80 54
All 1 models by family
Asset-Based
NCAV (Graham) $5.40 $7.24 $10.80 54

Open the full fair value analysis →

Notify me when SRPT reaches fair value

Put SRPT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 35/100

Of which business quality 33 · Market factors (momentum, volatility) 36

Profitability 23
Margins and returns on capital today
Quality Growth 34
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 46
Balance sheet, leverage, solvency risk
Investment 58
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 59
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.4%
Start year 2020 (pandemic)
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−104.5% (2020) → −29.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SRPT screens overvalued: fair value 82% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sarepta Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −82.3% · Bottom 25%
Profitability
Return on equity (TTM) 4.9% · Above median
Return on assets 0.0% · Above median
Net margin (TTM) 3.0% · Below median
Operating margin (TTM) 49.1% · Top 25%
Growth and dividend
Revenue growth −1.9% · Below median
Balance sheet
Debt / equity 0.73× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 51.5× · Pricier than median
P/B 1.61× · Cheaper than median
P/S (TTM) 0.84× · Cheapest 25%
EV/EBITDA 40.5× · Priciest 25%
PEG 159.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)20 · sector 0
HEALTH (low debt)64 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sarepta Therapeutics Inc · Fair Value
$3.11 −82%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sarepta Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/SRPT

Frequently asked questions

Is Sarepta Therapeutics Inc (SRPT) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.11 versus a price of $17.50, about −82% upside (overvalued).
What is the fair value of SRPT?
Our model-based fair value for Sarepta Therapeutics Inc is $3.11 (as of Sep 24, 2026), built from audited fundamentals. The current price: $17.50.
What is the quality score of SRPT?
Sarepta Therapeutics Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sarepta Therapeutics Inc (SRPT)?
Our model-based price target is the fair value of $3.11 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $2.06, optimistic scenario $3.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Sarepta Therapeutics Inc stock forecast for 2026?
Our models put fair value at $3.11, about −82% upside versus a price of $17.50 (overvalued). Cautious scenario $2.06, optimistic scenario $3.89. The calculation is refreshed regularly with new filings.
What is the revenue of Sarepta Therapeutics Inc (SRPT)?
Sarepta Therapeutics Inc reported trailing-twelve-month revenue of about $2.2B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Sarepta Therapeutics Inc (SRPT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sarepta Therapeutics Inc it is $3.11 per share (as of Sep 24, 2026), against a price of $17.50. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sarepta Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SRPT trades above its calculated fair value: price $17.50, fair value $3.11, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRPT?
No. The price is what the market pays today ($17.50); the fair value is what the company's own numbers justify ($3.11). For Sarepta Therapeutics Inc the two are $14.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sarepta Therapeutics Inc worth?
The market values Sarepta Therapeutics Inc at about $1.8B (market capitalisation, as of Sep 24, 2026). Per share that is $17.50; our models calculate a fair value of $3.11 per share.
What do the bullish and bearish scenarios say about SRPT?
Our models span a range for Sarepta Therapeutics Inc: cautious scenario $2.06, base $3.11, optimistic $3.89 per share (as of Sep 24, 2026, price $17.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SRPT?
Sarepta Therapeutics Inc trades at a price-to-earnings ratio of 51.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.11 is built from several models across several years. Other multiples: PEG 159.3, P/B 1.6, P/S 0.8, EV/EBITDA 40.5.
What is the PEG ratio of SRPT?
The PEG ratio of Sarepta Therapeutics Inc is 159.25 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sarepta Therapeutics Inc (SRPT)?
Balance-sheet figures for Sarepta Therapeutics Inc (as of Sep 24, 2026): return on equity 4.9%, debt of 0.73 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is SRPT from its 52-week high?
Sarepta Therapeutics Inc trades at $17.50, about 28% below its 52-week high of $24.45 and 18% above the low of $14.86 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $3.11 is for.
Which stocks are comparable to Sarepta Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sarepta Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $17.50, calculated fair value $3.11 (−82%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SRPT calculated?
We run Sarepta Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.11, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sarepta Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sarepta Therapeutics Inc (SRPT)?
The closing price on Oct 2, 2026 was $17.50. Our model-based fair value is $3.11, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sarepta Therapeutics Inc right now?
The price sits above even our optimistic bull case ($3.89). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.06 to $3.89) leaves room in how you read the outcome.

Key figures of Sarepta Therapeutics Inc

How large is the market capitalisation of Sarepta Therapeutics Inc (SRPT)?
The market capitalisation of Sarepta Therapeutics Inc is $1.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sarepta Therapeutics Inc (SRPT)?
The price-to-sales ratio of Sarepta Therapeutics Inc is 0.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sarepta Therapeutics Inc (SRPT)?
Earnings per share at Sarepta Therapeutics Inc are $0.3400 (price ÷ EPS = P/E 51.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sarepta Therapeutics Inc (SRPT)?
The net margin of Sarepta Therapeutics Inc is −32.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sarepta Therapeutics Inc (SRPT)?
The return on equity (ROE) of Sarepta Therapeutics Inc is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sarepta Therapeutics Inc (SRPT)?
On an EBIT basis the return on assets of Sarepta Therapeutics Inc is −10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sarepta Therapeutics Inc (SRPT)?
The operating margin of Sarepta Therapeutics Inc is 49.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sarepta Therapeutics Inc (SRPT)?
Revenue at Sarepta Therapeutics Inc is growing −1.9% versus a year earlier (3y avg +33.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sarepta Therapeutics Inc (SRPT)?
Earnings per share at Sarepta Therapeutics Inc are growing +26.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sarepta Therapeutics Inc (SRPT) generate?
The free cash flow of Sarepta Therapeutics Inc is −$307M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sarepta Therapeutics Inc (SRPT) carry?
The net debt of Sarepta Therapeutics Inc is $238M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sarepta Therapeutics Inc in the live analysis

One click puts Sarepta Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.